Elevated Serum Immune Mediators and Subclinical Inflammation in HLA-A29-associated Birdshot Chorioretinopathy

REFERENCES

• Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol. 2005;50:519–541.
   PubMed Web of Science ®Google Scholar
• Monnet D, Brezin AP. Birdshot chorioretinopathy. Curr Opin Ophthalmol. 2006;17:545–550.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Mittal KK, Ryan S, et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol. 1982;94:147–158.
   PubMed Web of Science ®Google Scholar
• Wee R, Papaliodis G. Genetics of birdshot chorioretinopathy. Semin Ophthalmol. 2008;23:53–57.
   PubMedGoogle Scholar
• Holak HM, Szymaniec S, Holak SA. The pathogenesis of birdshot chorioretinopathy. Surv Ophthalmol. 2006;51:446–447; author reply 447.
   Google Scholar
• Donvito B, Monnet D, Tabary T, et al. A new HLA extended haplotype containing the A*2910 allele in birdshot retinochoroidopathy: susceptibility narrowed to the HLA molecule itself. Invest Ophthalmol Vis Sci. 2010;51:2525–2528.
   PubMed Web of Science ®Google Scholar
• Boisgerault F, Khalil I, Tieng V, et al. Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Proc Natl Acad Sci U S A. 1996;93:3466–3470.
   PubMed Web of Science ®Google Scholar
• Gaudio PA, Kaye DB, Crawford JB. Histopathology of birdshot retinochoroidopathy. Br J Ophthalmol. 2002;86:1439–1441.
   PubMed Web of Science ®Google Scholar
• Pulido JS, Canal I, Salomao D, et al. Histological findings of birdshot chorioretinopathy in an eye with ciliochoroidal melanoma. Eye (Lond). 2012;26:862–865.
   PubMed Web of Science ®Google Scholar
• Kiss S, Ahmed M, Letko E, et al. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112:1066–1071.
   PubMed Web of Science ®Google Scholar
• Becker MD, Wertheim MS, Smith JR, et al. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm. 2005;13:289–293.
   PubMed Web of Science ®Google Scholar
• Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888–898.
   PubMed Web of Science ®Google Scholar
• Holtta V, Klemetti P, Sipponen T, et al. IL-23/IL-17 immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis. 2008;14:1175–1184.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–442.
   PubMed Web of Science ®Google Scholar
• Kuiper JJ, Mutis T, de Jager W, et al. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol. 2011;152:177–182e171.
   PubMed Web of Science ®Google Scholar
• Yang P, Foster CS. Interleukin 21, interleukin 23, and transforming growth factor beta1 in HLA-A29-associated birdshot retinochoroidopathy. Am J Ophthalmol. 2013;156:400–406e402.
   PubMed Web of Science ®Google Scholar
• Levinson RD, Brezin A, Rothova A, et al. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol. 2006;141:185–187.
   PubMed Web of Science ®Google Scholar
• Kruh JN, Yang P, Suelves AM, et al. Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358–364.
   PubMed Web of Science ®Google Scholar
• Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behcet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–210.
   PubMed Web of Science ®Google Scholar
• Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49:3058–3064.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenc V, et al. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behcet’s disease. Mediators Inflamm. 2014;2014:396204.
   PubMed Web of Science ®Google Scholar
• Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110:55–62.
   PubMed Web of Science ®Google Scholar
• Nishikawa K, Seo N, Torii M, et al. Interleukin-17 induces an atypical M2-like macrophage subpopulation that regulates intestinal inflammation. PLoS One. 2014;9:e108494.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov, II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–974.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238.
   PubMed Web of Science ®Google Scholar
• Dillon SM, Rogers LM, Howe R, et al. Human intestinal lamina propria CD1c+ dendritic cells display an activated phenotype at steady state and produce IL-23 in response to TLR7/8 stimulation. J Immunol. 2010;184:6612–6621.
   PubMed Web of Science ®Google Scholar
• Jefford M, Schnurr M, Toy T, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood. 2003;102:1753–1763.
   PubMed Web of Science ®Google Scholar
• Yu CI, Becker C, Wang Y, et al. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-beta. Immunity. 2013;38:818–830.
   PubMed Web of Science ®Google Scholar
• Chen P, Denniston A, Hannes S, et al. Increased CD1c(+) mDC1 with mature phenotype regulated by TNFalpha-p38 MAPK in autoimmune ocular inflammatory disease. Clin Immunol. 2015;158:35–46.
   PubMed Web of Science ®Google Scholar
• Kuiper JJ, Van Setten J, Ripke S, et al. A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy. Hum Mol Genet. 2014;23:6081–6087.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10:479–489.
   PubMed Web of Science ®Google Scholar
• Passos ST, Silver JS, O’Hara AC, et al. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J Immunol. 2010;184:1776–1783.
   PubMed Web of Science ®Google Scholar
• Dagur PK, Biancotto A, Stansky E, et al. Secretion of interleukin-17 by CD8+ T cells expressing CD146(MCAM). Clin Immunol. 2014;152:36–47.
   PubMed Web of Science ®Google Scholar
• Kuiper JJ, Rothova A, Schellekens PA, et al. Detection of choroid- and retina-antigen reactive CD8(+) and CD4(+) T lymphocytes in the vitreous fluid of patients with birdshot chorioretinopathy. Hum Immunol. 2014;75:570–577.
   PubMed Web of Science ®Google Scholar
• Liu X, Yang P, Lin X, et al. Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2009;131:333–342.
   PubMed Web of Science ®Google Scholar
• Molins B, Mesquida M, Lee RW, et al. Regulatory T cell levels and cytokine production in active non-infectious uveitis: in-vitro effects of pharmacological treatment. Clin Exp Immunol. 2015;179:529–538.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777–787.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122:939–948.
   PubMed Web of Science ®Google Scholar
• Adan A, Mesquida M, Llorenc V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–545.
   PubMed Web of Science ®Google Scholar